01
Cash & equivalents increased 350.2%
Cash & equivalents changed +350.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$20.6M→$92.7MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTLarimar Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +350.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -25.2% from the comparable as-filed period.
Operating income changed -23.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LRMR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-331529SEC ↗8-KAug 4, 2026Period Aug 4, 20260001193125-26-331516SEC ↗4Jul 8, 2026Period Jul 6, 20260001193125-26-298523SEC ↗8-KJun 29, 2026Period Jun 29, 20260001193125-26-286780SEC ↗4May 20, 2026Period May 19, 20260001193805-26-000669SEC ↗4May 20, 2026Period May 19, 20260001193125-26-232933SEC ↗4May 20, 2026Period May 19, 20260001193125-26-232705SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 6, 2026Filed Jul 8, 2026 | Hamilton Thomas EdwardDirector | Open Market PurchaseDirect | 50,000 | $3 | $166,890 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +19.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +17.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-232667